Source: Oncolytics Biotech Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The 2023 American Society of Clinical Oncology (ASCO) will see a return of in-person attendance with 40,000 people already registered
  • Presentations are set from some of the biotech sector’s most notable names
  • The ASCO annual meeting will be held in Chicago from June 2 to 6, 2023
  • Invitae Corp. (NVTA) opened trading at C$1.49 and Oncolytics Biotech Inc. (ONC) opened trading at C$2.85 per share

Next week, top health care firms will converge or the biggest cancer conference in the world.

The 2023 American Society of Clinical Oncology (ASCO) will see a return of in-person attendance with 40,000 people already registered.

Presentations are set from some of the biotech sector’s most notable names. Invitae (NYSE:NVTA), a leading medical genetics company, announced on Friday that nine studies will be presented.

The new research insights highlight innovations in genetic testing in a variety of clinical settings, population groups and cancer types, and reinforce the need to reduce barriers to genetic services to help patients receive the most effective care and monitoring.

Oncolytics Biotech (NASDAQ:ONCY / TSX:ONC) announced that positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer will be presented at ASCO.

The BRACELET-1 (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-Land Paclitaxel) is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement with Pfizer Inc. (NYSE:PFE) and Merck KGaA, Darmstadt, Germany.

The ASCO annual meeting will be held in Chicago from June 2 to 6, 2023. To find out more about Oncolytics’ study that will be featured at the event, click here.

Invitae Corp. (NVTA) opened trading at C$1.49 and Oncolytics Biotech Inc. (ONC) opened trading at C$2.85 per share.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Herald
Else Nutrition

" Else expands distribution with Canada’s largest pharmacy retailer

Else Nutrition Holdings (BABY) has expanded its distribution in the Canadian market with Canada’s largest pharmacy.
Danavation - President and CEO, John Ricci (eighth from left).

" Smart label company signs multi-location contract in Quebec

Smart label company Danavation has announced a multi-store contract with Pitou Minou & Compagnons in Quebec.

" Westhaven drills 24.95 metres of 14.66 g/t gold and 35.52 g/t of silver

Westhaven Gold’s (TSXV:WHN) Shovel Nose property continues to intersect high-grade gold near surface at the Franz Zone.

" Snowline Gold begins drill program in Yukon

Snowline Gold (V.SGD) begins drill program at its Yukon exploration projects.